Advertisement

 

 

RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.

RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.
Author Information (click to view)

Earwaker P, Anderson C, Willenbrock F, Harris AL, Protheroe AS, Macaulay VM,


Earwaker P, Anderson C, Willenbrock F, Harris AL, Protheroe AS, Macaulay VM, (click to view)

Earwaker P, Anderson C, Willenbrock F, Harris AL, Protheroe AS, Macaulay VM,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PloS one 2018 02 0113(2) e0191890 doi 10.1371/journal.pone.0191890
Abstract

The outlook for patients with advanced renal cell cancer (RCC) has been improved by targeted agents including inhibitors of the PI3 kinase (PI3K)-AKT-mTOR axis, although treatment resistance is a major problem. Here, we aimed to understand how RCC cells acquire resistance to PI3K-mTOR inhibition. We used the RCC4 cell line to generate a model of in vitro resistance by continuous culture in PI3K-mTOR kinase inhibitor NVP-BEZ235 (BEZ235, Dactolisib). Resistant cells were cross-resistant to mTOR inhibitor AZD2014. Sensitivity was regained after 4 months drug withdrawal, and resistance was partially suppressed by HDAC inhibition, supporting an epigenetic mechanism. BEZ235-resistant cells up-regulated and/or activated numerous proteins including MET, ABL, Notch, IGF-1R, INSR and MEK/ERK. However, resistance was not reversed by inhibiting or depleting these pathways, suggesting that many induced changes were passengers not drivers of resistance. BEZ235 blocked phosphorylation of mTOR targets S6 and 4E-BP1 in parental cells, but 4E-BP1 remained phosphorylated in resistant cells, suggesting BEZ235-refractory mTORC1 activity. Consistent with this, resistant cells over-expressed mTORC1 component RAPTOR at the mRNA and protein level. Furthermore, BEZ235 resistance was suppressed by RAPTOR depletion, or allosteric mTORC1 inhibitor rapamycin. These data reveal that RAPTOR up-regulation contributes to PI3K-mTOR inhibitor resistance, and suggest that RAPTOR expression should be included in the pharmacodynamic assessment of mTOR kinase inhibitor trials.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 × two =

[ HIDE/SHOW ]